Integrin alpha V beta 3 Antibody (23C6) [Alexa Fluor® 488]

HUVEC human umbilical vein endothelial cells were stained with Mouse Anti-Human Integrin aV beta 3 Alexa Fluor® 488-conjugated Monoclonal Antibody (Catalog # FAB3050G, filled histogram) or isotype control antibody (Catalog # IC002G, open histogram). View our protocol for Staining Membrane-associated Proteins.

• Reactivity: Hu
• Applications: Flow
• Clone: 23C6
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Alexa Fluor 488

Integrin alpha V beta 3 Antibody (23C6) [Alexa Fluor® 488] Summary

• Immunogen: Human osteoclasts
• Specificity: Detects human Integrin alpha V beta 3.
• Source: N/A
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Gene: ITGAV
• Purity Statement: Protein A or G purified from hybridoma culture supernatant

Applications/Dilutions

• Dilutions:
  • Flow Cytometry 5 uL/10^6 cells

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze.
  • 12 months from date of receipt, 2 to 8 °C as supplied.
• Buffer: Supplied in a saline solution containing BSA and Sodium Azide.
• Preservative: Sodium Azide

Notes

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Integrin alpha V beta 3 Antibody (23C6) [Alexa Fluor® 488]

• antigen identified by monoclonal L230
• CD51 antigen
• CD51
• Integrin alpha V beta 3
• integrin alpha-V
• integrin, alpha V (vitronectin receptor, alpha polypeptide, antigen CD51)
• MSK8
• Vitronectin receptor subunit alpha
• VNRADKFZp686A08142

Background

Integrin alpha V beta 3 together with alpha IIb beta ₃, constitutes the only known beta 3 Integrins (1-3). The non-covalent heterodimer of 170 kDa alpha V/CD51 and 93 kDa beta ₃/CD61 subunits shows wide expression, notably by endothelial cells and osteoclasts (2-4). Each subunit has a transmembrane sequence and a short cytoplasmic tail connected to the cytoskeleton. Active cell surface alpha V beta 3 adheres to matrix proteins including vitronectin, fibronectin, fibrinogen and thrombospondin (2, 3). The ligand binding site of alpha V beta 3 is in the N-terminal head region, formed by interaction of the beta 3 vWFA domain with the alpha V beta-propeller structure (4). The alpha V subunit contributes a thigh and a calf region, while the beta 3 subunit contains a PSI domain and four cysteine-rich I-EGF folds. The alpha V subunit domains termed thigh, calf-1 and calf-2 generate a “knee” region that is bent when the alpha V beta 3 is in its constitutively inactive state. Activation, either by “inside out” signaling or by Mg²⁺ or Mn²⁺ binding, extends the Integrin to expose its ligand binding site (1, 4). Two splice variants of beta 3 (b and c) diverge over the last 21 amino acids (aa) and lack cytoplasmic phosphorylation sites (5, 6). Another beta 3 splice variant diverges after the vWFA domain, producing a soluble 60 kDa form in platelets and endothelial cells (7). alpha V beta 3 is essential for the maturation of osteoclasts and their binding and resorption of bone; it also, however, promotes their apoptosis (8, 9). M-CSF R and alpha V beta 3 share signaling pathways during osteoclastogenesis, and deletion of either molecule causes osteopetrosis (8, 9). Also cell entry of several viruses is mediated by alpha V beta 3 (4, 10). The 962 aa human alpha V ECD (11) shares 92‑95% aa sequence identity with mouse, rat and cow  alpha V while the 685 aa human beta ₃ ECD (12) shares 95% aa identity with horse and dog, and 89‑92% aa identity with mouse, rat and pig beta ₃.

1. Hynes, R. O. (2002) Cell 110:673.
2. Serini, G. et al. (2006) Exp. Cell Res. 312:651.
3. Ross, F. P. and S. L. Teitelbaum (2005) Immunol. Rev. 208:88.
4. Xiong, J. et al. (2001) Science 294:339.
5. Kumar, C. S. et al. (1987) J. Biol. Chem. 272:16390.
6. vanKuppevelt, H. et al. (1989) Proc. Natl. Acad. Sci. USA 86:5415.
7. Djaffar, I. et al. (1994) Biochem. J. 300:67.
8. McHugh, K. P. et al. (2000) J. Clin. Invest. 105:433.
9. Faccio, R. et al. (2003) J. Clin. Invest. 111:749.
10. Chu, J. J. and M. Ng (2004) J. Biol. Chem. 279:54533.
11. Suzuki, S. et al. (1987) J. Biol. Chem. 262:14060.
12. Fitzgerald, L. A. et al. (1987) J. Biol. Chem. 262:3936.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for Integrin alpha V beta 3 Antibody (FAB3050G)(2)

Publications using FAB3050G

• H Huang, Y Dong, Y Zhang, D Ru, Z Wu, J Zhang, M Shen, Y Duan, Y Sun GSH-sensitive Pt(IV) prodrug-loaded phase-transitional nanoparticles with a hybrid lipid-polymer shell for precise theranostics against ovarian cancer Theranostics, 2019-01-30;9(4):1047-1065. 2019-01-30 [PMID: 30867815] (Flow Cytometry, Human)
• Seung Woo Chung, Jeong Uk Choi, Young Seok Cho, Ha Rin Kim, Tae Hyung Won, Peter Dimitrion et al. Self-Triggered Apoptosis Enzyme Prodrug Therapy (STAEPT): Enhancing Targeted Therapies via Recurrent Bystander Killing Effect by Exploiting Caspase-Cleavable Linker Advanced Science 7/1/2018 [PMID: 30027061]

Bioinformatics

• Gene Symbol: ITGAV